Similarly, the Oncoguard Liver test, which combines methylation biomarkers such as HOXA1, TSPYL5, and B3GALT6 with sex and AFP, demonstrated a sensitivity of 72% (95% CI: 61–80%) and specificity of 88% (95 CI: 84–91%) for detecting early-stage HCC in the algorithm development study. The gene discussed is AFP; the disease is hepatocellular carcinoma.